Q-omics provides the consensus-scored CPNE8 profile across patient tissues and cancer cell-line models. CPNE8 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CPNE8 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, CPNE8 RNA expression shows 19,483 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where CPNE8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CPNE8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CPNE8 survival associations across molecular data types. CPNE8 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CPNE8 RNA expression–survival associations across cancer types. High CPNE8 expression shows unfavorable associations in STAD, ACC, MESO, LAML and HNSC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CPNE8 RNA expression.
This table summarizes CPNE8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CPNE8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CPNE8 shows lower tumor expression in COAD, KICH, THCA and UCEC and higher tumor expression in HNSC and KIRC. The HNSC box plot shows higher CPNE8 RNA expression in tumor versus normal tissue (log2 FC = +1.357, t-test p < 0.001).
This table shows molecular features associated with CPNE8 in patient tissues and cancer cell lines. In patient samples, CPNE8 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CPNE8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
